In collaboration with Osivax, we are investigating immune responses elicited by next-generation universal vaccine candidates targeting highly mutable respiratory viruses. Leveraging our expertise in human immunology and single-cell technologies, we characterize vaccine-induced T-cell responses and define the cellular mechanisms that underpin durable and broad protective immunity. These studies support the development of innovative vaccines designed to provide long-lasting protection against current and emerging viral variants.